These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2369809)

  • 1. Transintestinal elimination of ciprofloxacin.
    Rohwedder RW; Bergan T; Thorsteinsson SB; Scholl H
    Diagn Microbiol Infect Dis; 1990; 13(2):127-33. PubMed ID: 2369809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transintestinal elimination of ciprofloxacin.
    Rohwedder R; Bergan T; Thorsteinsson SB; Scholl H
    Chemotherapy; 1990; 36(2):77-84. PubMed ID: 2311444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the pharmacology of intravenously administered ciprofloxacin.
    Drusano GL
    Am J Med; 1987 Apr; 82(4A):339-45. PubMed ID: 3578325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.
    Bergan T
    J Chemother; 1989 Feb; 1(1):10-7. PubMed ID: 2542469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
    Yu H; Wang HY; Sun ZM
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function.
    Mahon WA; Johnson GE; Endrenyl L; Kelly MF; Fenton SS
    Scand J Infect Dis Suppl; 1976; (9):24-31. PubMed ID: 1070145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of iopentol in patients with chronic renal failure.
    Svaland MG; Kolmannskog F; Lillevold PE; Nordal KP; Ressem L; Berg KJ
    Acta Radiol; 1992 Sep; 33(5):482-4. PubMed ID: 1389660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
    Prescott LF; Freestone S; McAuslane JA
    Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
    Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
    Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure.
    Cayen MN; Ferdinandi ES; Hicks DR; Gonzalez R; Cosyns L; Dubuc J; Kraml M; Edwards KD
    Clin Pharmacol Ther; 1990 Jan; 47(1):50-6. PubMed ID: 2295219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
    Lorusso V; Taroni P; Alvino S; Spinazzi A
    Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
    Frost RW; Lettieri JT; Krol G; Shamblen EC; Lasseter KC
    Clin Pharmacol Ther; 1989 Jun; 45(6):608-16. PubMed ID: 2731404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.
    Singlas E; Taburet AM; Landru I; Albin H; Ryckelinck JP
    Eur J Clin Pharmacol; 1987; 31(5):589-93. PubMed ID: 3830244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.